{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-066526","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-06-09T11:30:47+00:00","discovered_at":"2026-06-09T11:35:00.254546+00:00","generated_at":"2026-06-09T11:35:29.464842+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Incannex initiates research coverage by Alliance Global Partners with BUY rating, $18 PT","bullets":["Alliance Global Partners (AGP) initiates coverage with BUY rating and $18.00 price target as of June 8, 2026.","Analyst James Molloy, AGP Managing Director and Senior Biotechnology Analyst, authored the report.","Incannex's lead programs: IHL-42X for obstructive sleep apnoea (DReAMzz study) and PSX-001 synthetic psilocybin for generalized anxiety disorder.","AGP has received compensation from Incannex for providing investment banking services."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-066526","json":"https://secwatch.observer/filing/0001213900-26-066526.json","markdown":"https://secwatch.observer/filing/0001213900-26-066526.md","text":"https://secwatch.observer/filing/0001213900-26-066526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026066526/0001213900-26-066526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026066526/ea0293934-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:35:29.464842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}